SK284412B6 - Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi - Google Patents

Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi Download PDF

Info

Publication number
SK284412B6
SK284412B6 SK807-98A SK80798A SK284412B6 SK 284412 B6 SK284412 B6 SK 284412B6 SK 80798 A SK80798 A SK 80798A SK 284412 B6 SK284412 B6 SK 284412B6
Authority
SK
Slovakia
Prior art keywords
danofloxacin
solution
aqueous pharmaceutical
polyvinylpyrrolidone
pharmaceutical solution
Prior art date
Application number
SK807-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK80798A3 (en
Inventor
Wayne Alan Boettner
Peter Connor Canning
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284412(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK80798A3 publication Critical patent/SK80798A3/sk
Publication of SK284412B6 publication Critical patent/SK284412B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK807-98A 1995-12-21 1996-11-13 Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi SK284412B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21
PCT/IB1996/001217 WO1997023217A1 (en) 1995-12-21 1996-11-13 Injectable quinolone formulations

Publications (2)

Publication Number Publication Date
SK80798A3 SK80798A3 (en) 1999-09-10
SK284412B6 true SK284412B6 (sk) 2005-03-04

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
SK807-98A SK284412B6 (sk) 1995-12-21 1996-11-13 Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi

Country Status (42)

Country Link
US (1) US5811130A (xx)
EP (1) EP0868183B1 (xx)
JP (1) JP3416145B2 (xx)
KR (1) KR100402570B1 (xx)
CN (1) CN1104899C (xx)
AP (1) AP706A (xx)
AR (1) AR005147A1 (xx)
AT (1) ATE212551T1 (xx)
AU (1) AU709474B2 (xx)
BG (1) BG63933B1 (xx)
BR (1) BR9612230A (xx)
CA (1) CA2239352C (xx)
CO (1) CO4480098A1 (xx)
CZ (1) CZ293747B6 (xx)
DE (1) DE69618987T2 (xx)
DK (1) DK0868183T3 (xx)
DZ (1) DZ2146A1 (xx)
EG (1) EG24071A (xx)
ES (1) ES2167609T3 (xx)
GT (1) GT199600098A (xx)
HR (1) HRP960607B1 (xx)
HU (1) HU227918B1 (xx)
IL (1) IL124454A (xx)
IS (1) IS2010B (xx)
MA (1) MA24035A1 (xx)
MX (1) MX9805026A (xx)
MY (1) MY117109A (xx)
NO (1) NO315734B1 (xx)
NZ (2) NZ320545A (xx)
OA (1) OA10697A (xx)
PE (1) PE25798A1 (xx)
PL (1) PL186795B1 (xx)
PT (1) PT868183E (xx)
RS (1) RS49523B (xx)
RU (1) RU2141827C1 (xx)
SI (1) SI0868183T1 (xx)
SK (1) SK284412B6 (xx)
TN (1) TNSN96163A1 (xx)
TW (1) TW449475B (xx)
UA (1) UA56151C2 (xx)
WO (1) WO1997023217A1 (xx)
ZA (1) ZA9610780B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
CA2488526A1 (en) * 2002-06-26 2004-01-08 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
US20090117205A1 (en) * 2004-07-02 2009-05-07 Daiichi Pharmaceutical Co., Ltd Quinolone-containing medicinal composition
PT2594272T (pt) * 2005-05-18 2018-07-31 Horizon Orphan Llc Fluoroquinolonas aerossolizadas e suas utilizações
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
WO2007090646A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
WO2016195014A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
AU2018217931B2 (en) * 2017-02-13 2023-04-13 Elanco Animal Health Gmbh Liquid composition containing pradofloxacin
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
ES2102393T3 (es) * 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HRP960607B1 (en) 2002-06-30
BG102542A (en) 1999-06-30
HRP960607A2 (en) 1998-06-30
HUP9903726A2 (hu) 2000-04-28
HU227918B1 (en) 2012-06-28
CN1205636A (zh) 1999-01-20
BG63933B1 (bg) 2003-07-31
RU2141827C1 (ru) 1999-11-27
TNSN96163A1 (fr) 2005-03-15
CZ193098A3 (cs) 1999-05-12
PE25798A1 (es) 1998-05-21
MA24035A1 (fr) 1997-07-01
BR9612230A (pt) 1999-07-13
IL124454A0 (en) 1998-12-06
YU69096A (sh) 1999-06-15
CO4480098A1 (es) 1997-07-09
SK80798A3 (en) 1999-09-10
SI0868183T1 (en) 2002-04-30
KR19990076617A (ko) 1999-10-15
DZ2146A1 (fr) 2002-10-23
PT868183E (pt) 2002-06-28
JPH11501331A (ja) 1999-02-02
NO315734B1 (no) 2003-10-20
IS4755A (is) 1998-05-25
TW449475B (en) 2001-08-11
AU7328996A (en) 1997-07-17
NO982842D0 (no) 1998-06-19
ATE212551T1 (de) 2002-02-15
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
CN1104899C (zh) 2003-04-09
CA2239352A1 (en) 1997-07-03
OA10697A (en) 2001-05-04
DE69618987T2 (de) 2002-11-21
CA2239352C (en) 2002-06-04
NO982842L (no) 1998-06-19
DE69618987D1 (de) 2002-03-14
PL186795B1 (pl) 2004-02-27
DK0868183T3 (da) 2002-03-25
MX9805026A (es) 1998-09-30
JP3416145B2 (ja) 2003-06-16
NZ320545A (en) 2000-03-27
CZ293747B6 (cs) 2004-07-14
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
IL124454A (en) 2003-10-31
PL328001A1 (en) 1999-01-04
MY117109A (en) 2004-05-31
EP0868183B1 (en) 2002-01-30
EG24071A (en) 2008-05-11
US5811130A (en) 1998-09-22
ZA9610780B (en) 1998-06-22
ES2167609T3 (es) 2002-05-16
IS2010B (is) 2005-05-13
AP9600898A0 (en) 1997-01-31
KR100402570B1 (ko) 2003-12-18
HUP9903726A3 (en) 2001-01-29
NZ501160A (en) 2001-10-26
AR005147A1 (es) 1999-04-14
UA56151C2 (uk) 2003-05-15
WO1997023217A1 (en) 1997-07-03
GT199600098A (es) 1998-06-12

Similar Documents

Publication Publication Date Title
SK284412B6 (sk) Vodný farmaceutický roztok vhodný na injekčné podávanie hostiteľovi
CS205030B2 (en) Method of producing of the stabil antibiotic means
JP2003505419A (ja) ケトチフェンを含む眼用組成物
US4772460A (en) Method of reducing the swelling or pain associated with antibiotics compositions
US7094414B2 (en) Famotidine injections
EP0769951B1 (en) Long-acting oxytetracycline composition
US20090117205A1 (en) Quinolone-containing medicinal composition
US6110905A (en) Long-acting oxytetracycline composition
EP0365363B1 (en) Parenteral formulations of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]piperazine
US5753636A (en) Injection solution for intramuscular and subcutaneous administration to animals
JPS6348217A (ja) 麻酔薬組成物
SK3032003A3 (en) Method for producing peptide salts, their use and pharmaceutical preparations containing these peptide salts
US5063220A (en) Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine
NZ208091A (en) Injectable solutions containing oxytetracycline and magnesium
FI57883C (fi) Foerfarande foer framstaellning av en stabil klortetracyklinloesning
JPS5951272A (ja) ２−（ヘキサヒドロアゼピノ）−ｎ−（２，６−ジメチルフエニル）−アセトアミド、その製造法及びそれを含む医薬

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: AH USA 42 LLC, NEW YORK, NY, US

Free format text: FORMER OWNER: PFIZER INC., NEW YORK, NY, US

Effective date: 20121001

TC4A Change of owner's name

Owner name: ZOETIS LLC, FLORHAM PARK, NEW JERSEY, US

Effective date: 20130712

PC4A Assignment and transfer of rights

Owner name: ZOETIS SERVICES LLC, FLORHAM PARK, NJ, US

Free format text: FORMER OWNER: ZOETIS LLC, FLORHAM PARK, NEW JERSEY, US

Effective date: 20160127

MK4A Expiry of patent

Expiry date: 20161113